Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $9.36 USD
Change Today -0.19 / -1.99%
Volume 413.8K
SCLN On Other Exchanges
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

sciclone pharmaceuticals inc (SCLN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/8/15 - $11.71
52 Week Low
08/1/14 - $4.74
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sciclone pharmaceuticals inc (SCLN) Related Bloomberg News

View More Bloomberg News

sciclone pharmaceuticals inc (SCLN) Related Businessweek News

No Related Businessweek News Found

sciclone pharmaceuticals inc (SCLN) Details

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People’s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. The company also focuses on development ZADAXIN for the treatment of sepsis. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, Eastern Europe, and the Middle East regions. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. In addition, it markets approximately seven partnered products in China, including Aggrastat, an interventional cardiology product. Further, the company holds license, promotion, distribution, or marketing agreements with various parties for products, including DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, ProFlow, Angiomax, and Cleviprex. SciClone Pharmaceuticals, Inc. also has an agreement with MEDA Pharma GmbH & Co. KG for the development of Tramadol. The company was founded in 1989 and is headquartered in Foster City, California.

570 Employees
Last Reported Date: 03/12/15
Founded in 1989

sciclone pharmaceuticals inc (SCLN) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $566.5K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $356.5K
Chief Executive Officer of China Operations
Total Annual Compensation: $543.4K
Vice President of Compliance and General Coun...
Total Annual Compensation: $448.3K
Vice President of Finance and Chief Financial...
Total Annual Compensation: $301.1K
Compensation as of Fiscal Year 2014.

sciclone pharmaceuticals inc (SCLN) Key Developments

SciClone Pharmaceuticals, Inc. and Theravance Biopharma, Inc. Enter into Development and Commercialization Agreement for VIBATIV(r) (Telavancin) in China

SciClone Pharmaceuticals (SciClone) and Theravance Biopharma, Inc. (Theravance Biopharma), through an affiliate, announced they have entered into a development and commercialization agreement granting SciClone exclusive development and commercial rights for the antibiotic VIBATIV(r) (telavancin) in China and certain adjacent territories. The companies plan to pursue development and commercialization of VIBATIV in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). Additional indications may include complicated skin and skin structure infections (cSSSI), and potentially bacteremia. Under the terms of the agreement, Theravance Biopharma has granted SciClone exclusive development and commercialization rights to VIBATIV in China, as well as the Hong Kong SAR, the Macau SAR, Taiwan and Vietnam. In exchange, Theravance Biopharma will be eligible to receive upfront and regulatory milestone payments totaling $6 million. SciClone will be responsible for all aspects of development and commercialization in the partnered regions, including pre- and post-launch activities and product registration. Theravance Biopharma will sell to SciClone all clinical and commercial product required to develop and commercialize VIBATIV in China.

SciClone Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 10:00 AM

SciClone Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 10:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Wilson W. Cheung, Chief Financial Officer, Senior Vice President of Finance and Secretary.

SciClone Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

SciClone Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total net revenues of $33,568,000 against $26,565,000 a year ago. Income from operations was $9,483,000 against $4,661,000 a year ago. Income before provision for income tax was $9,532,000 against $4,532,000 a year ago. Net income was $8,962,000 against $4,134,000 a year ago. Diluted net income per share was $0.17 against $0.08 a year ago. Non-GAAP net income was $9,768,000 against $5,016,000 a year ago. Non-GAAP diluted net income per share was $0.19 against $0.09 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLN:US $9.36 USD -0.19

SCLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $47.01 USD +0.85
Lannett Co Inc $58.04 USD +1.86
Momenta Pharmaceuticals Inc $22.43 USD +0.46
Pernix Therapeutics Holdings Inc $5.17 USD -0.05
Sagent Pharmaceuticals Inc $25.47 USD -0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation SCLN Industry Range
Price/Earnings 16.7x
Price/Sales 3.4x
Price/Book 2.9x
Price/Cash Flow 15.8x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCICLONE PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at